Abstract
1525P - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have